RECOMBINATE 500 IU

Land: Israel

Sprog: engelsk

Kilde: Ministry of Health

Aktiv bestanddel:

COAGULATION FACTOR VIII RECOMBINANT 500 IU/VIAL

Tilgængelig fra:

TEVA MEDICAL MARKETING LTD.

ATC-kode:

B02BD05

Lægemiddelform:

POWDER FOR SOLUTION FOR INJECTION

Indgivelsesvej:

I.V

Fremstillet af:

BAXTER S.A., BELGIUM

Terapeutisk gruppe:

COAGULATION FACTOR VII

Terapeutiske indikationer:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

Autorisation dato:

2010-07-01